skip to main content columnskip to left navigationskip to horizontal navigation

Department of Internal Medicine

Quillen College of Medicine

Shunbin Ning, PhD | Infectious, Inflammatory and Immunologic Disease

Division Statement Faculty | Research/Scholarly Activities | Fellowship 

ning

Shunbin Ning, PhD | Associate Professor  | Infectious, Inflammatory and Immunologic Disease

VA Building 119, Room 206
423.439.8232

 

  

Graduate: Wuhan University, China, PhD, Cell Biology, Genetics 2001; BS, 1996, Cell Biology
Postdoc: UNC at Chapel Hill, 2002-2006, Tumor Virology & Immunology
Research Associate: UNC at Chapel Hill, 2007-2008, Tumor Virology & Immunology 

Brief Bio

Shunbin Ning, Ph.D., Associate Professor in the Department of Medicine, completed postdoctoral training at the University of North Carolina in Chapel Hill. Prior to joining the faculty, he was an assistant professor at the University of Miami, where he was active in the Sylvester Comprehensive Cancer Center.

RESEARCH INTERESTS

Chronic Viral Infection, Inflammation and Immunity, and Oncogenesis

Viruses contribute to more than 20% of all cancers worldwide. These virally induced malignant diseases are the leading cause of death in immunocompromised individuals with HIV co-infection, in which HIV has a direct pro-oncogenic property. As the first identified oncovirus, Epstein-Barr Virus (EBV/HHV4) is associated with a variety of lymphomas and carcinomas. EBV, along with Kaposi’s sarcoma- associated herpesvirus (KSHV) and human papillomavirus (HPV), is causally involved in AIDS-related malignancies (ARLs). EBV is also the etiological pathogen of Burkitt’s lymphoma (BL), Hodgkin lymphoma (HL), nasopharyngeal carcinoma (NPC) and infectious mononucleosis in immunocompetent individuals. Virus-associated lymphomas are often difficult to treat, due to their aggression (i.e. BL), the inadequate dose intensity, or exacerbation of infection in immunosuppressed patients.

Dr. Ning’s research interest is the interaction between AIDS-related oncogenic viruses (EBV, HCV, HTLV1) and the host innate immune system in developing cancers. The mechanistic studies involve DNA damage response (DDR), selective autophagy, ubiquitination, inflammaging and immunosenescence, and cell death. Deciphering the molecular events controlling the interaction between oncogenic viruses and cellular mechanisms related to host innate immune system will help us understand the role of innate immune system in viral oncogenesis and may identify potential targets for immunotherapeutic treatment for virus-associated diseases and cancers.

Dr. Ning serves on the editorial board of several journals including Annals of Clinical Virology, Annals of Inflammation Research, Trends in Immunotherapy, and International Journal of Immunology.

Representative Publications

1. Wang L, Howell M, Sparks-Wallace A, Hawkins C, Nicksic C, Kohne C, Moorman J, Yao Z, Ning S. p62-mediated Selective Autophagy Endows Virus-transformed Cells with Insusceptibility to DNA Damage under Oxidative Stress. PLoS Pathogens. 2019. In press.

2. Wang L, Howell M, McPeak B, Riggs K, Kohne C, Yohanon J.-U., Foxler DE, Sharp TV, Moorman JP, Yao ZQ, Ning S*. LIMD1 is induced by and required for LMP1 signaling, and protects EBV-transformed cells from DNA damage-induced cell death. Oncotarget. 2018. 9:6282-6297. PMID: 29464072.

3. Zhou J*, Yang X*, Ning S*, Wang L, Wang K, Zhang Y, Yuan F, Li F, Zhuo D, Tang L, Zhuo D. Identification of KANSARL as the First Cancer Predisposition Fusion Gene Specific to the Population of European Ancestry Origin. Oncotarget. 2017. 8(31):50594-50607. PMID: 28881586. PMCID: PMC5584173 (Highlighted at RNA-Seq blog). * Contributed equally to this project

4. Wang L, Wang Y, Zhao J, Ren J, Hall KH, Moorman JP, Yao ZQ, Ning S*. LUBAC modulates LMP1 activation of NFκB and IRF7. Journal of Virology. 2017. 91(4): e1138-16. PMID: 27903798

5. Wang L, Ren J, Li G, Moorman JP, Yao ZQ, Ning S. LMP1 Signaling Pathway Activates IRF4 in Latent EBV Infection and A Positive Circuit between PI3K and Src Is Required. Oncogene. 2017. 36(16):2265-2274. PMID: 27819673

6. Wang L, Zhao J, Ren J, Hall KH, Moorman JP, Yao ZQ, Ning S*. Protein Phosphatase 1 abrogates IRF7-mediated type I IFN response in antiviral immunity. European Journal of Immunology. 2016. 46(10):2409-2419. PMID: 27469204

7. Wang L, Zhao J, Ren JP, Wu XY, Morrison ZD, Elgazzar MA, Ning S, Moorman JP, Yao ZQ. Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals. AIDS. 2016. 30(10):1521-1531. PMID: 26959508.

8. Wang L, Yao Z, Jonathan M, Xu Y, Ning S. Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies. PLoS One. 2014. 9(9):e106788. PMID: 25207815

9. Wang L, Ning S. IRF4 is activated through c-Src-mediated tyrosine phosphorylation in virus-transformed cells. Journal of Virology. 2013. 87(17): 9672-9679. PMID: 23804646 (Chosen for “Spotlight” by the editors)

10. Wang L, Toomey NL, Diaz LA, Walker G, Ramos JC, Barber GN, Ning S. Oncogenic IRFs provide a survival advantage for EBV- or HTLV1- transformed cells through induction of BIC expression. Journal of Virology. 2011. 85(16): 8328-8337. PMID: 21680528

11. Ning S*, Pagano J. The A20 deubiquitinase activity negatively regulates ubiquitination-mediated LMP1 activation of IRF7. J. Virol. 2010. 84(12): 1630-1638. PMID: 20392859 * Corresponding author

12. Ling Wang, Shunbin Ning. "Toll-free" pathways for production of type I interferons. AIMS Allergy and Immunology. 2017. 1(3): 143-163. PMID: 29202128 Free full text PDF

13. Ling Wang, Guangyu Li, Zhi Q. Yao, Jonathan Moorman, Shunbin Ning. MicroRNA regulation of viral immunity, latency, and carcinogenesis of selected tumor viruses and HIV. Reviews in Medical Virology. 2015. 25: 320-341. Aug 10. doi: 10.1002/rmv.1850. [Epub ahead of print]. PMID: 26258805

icon for left menu icon for right menu